AR035137A1 - Composicion farmaceutica para inhibir metastasis o prevenir recurrencia de tumor maligno - Google Patents
Composicion farmaceutica para inhibir metastasis o prevenir recurrencia de tumor malignoInfo
- Publication number
- AR035137A1 AR035137A1 ARP020103077A ARP020103077A AR035137A1 AR 035137 A1 AR035137 A1 AR 035137A1 AR P020103077 A ARP020103077 A AR P020103077A AR P020103077 A ARP020103077 A AR P020103077A AR 035137 A1 AR035137 A1 AR 035137A1
- Authority
- AR
- Argentina
- Prior art keywords
- group
- formula
- active ingredient
- pharmaceutical composition
- possesses
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
Abstract
Una composición farmacéutica para inhibir metástasis o prevenir la recurrencia de un tumor maligno, que comprende como ingrediente activo un derivado de polisacárido que comprende un polisacárido que posee un grupo carboxilo unido a un ingrediente activo que posee una actividad antitumor por medio de un aminoácido o un péptido de 2 a 8 aminoácidos que son iguales o diferentes, o una sal del mismo. Preferentemente, el ingrediente activo que posee una actividad antitumor es un derivado de camptotecina de la fórmula (1) en donde R1 es un grupo alquilo inferior sustituido o sin sustituir; X1 es un grupo de la fórmula: -NHR2 (R2 es un átomo de hidrógeno o un grupo alquilo inferior) y Alk es un grupo alquileno C1-6 de cadena lineal o cadena ramificada que opcionalmente posee un átomo de oxígeno en la cadena del mismo, o un compuesto de la fórmula (2) en donde dos grupos de R2 a R6 que son adyacentes entre sí se combinan para formar un grupo alquileno inferior, y uno de los átomos del carbono de dicho grupo alquileno inferior es sustituido por un grupo amino, y los tres grupos de R2 a R6 restantes son un átomo de hidrógeno, un grupo alquilo inferior o un átomo de halógeno.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2001249717 | 2001-08-21 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR035137A1 true AR035137A1 (es) | 2004-04-14 |
Family
ID=19078678
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP020103077A AR035137A1 (es) | 2001-08-21 | 2002-08-15 | Composicion farmaceutica para inhibir metastasis o prevenir recurrencia de tumor maligno |
Country Status (18)
| Country | Link |
|---|---|
| EP (1) | EP1418947A1 (es) |
| KR (1) | KR20040027972A (es) |
| CN (1) | CN100372570C (es) |
| AR (1) | AR035137A1 (es) |
| AU (1) | AU2002328093B2 (es) |
| BR (1) | BR0212036A (es) |
| CA (1) | CA2457056C (es) |
| HU (1) | HUP0401351A3 (es) |
| IL (1) | IL160148A0 (es) |
| MX (1) | MXPA04001599A (es) |
| NO (1) | NO20041194L (es) |
| NZ (1) | NZ530947A (es) |
| PL (1) | PL368319A1 (es) |
| RU (1) | RU2275913C2 (es) |
| TW (1) | TWI313609B (es) |
| UA (1) | UA75450C2 (es) |
| WO (1) | WO2003015826A1 (es) |
| ZA (1) | ZA200400917B (es) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW200306314A (en) * | 2002-04-16 | 2003-11-16 | Tanabe Seiyaku Co | Liquid preparation comprising camptothecin derivative and pharmaceutical composition producible by lyophilizing the preparation |
| FR2914305B1 (fr) * | 2007-03-29 | 2009-07-03 | Proteins & Peptides Man | Dextran fonctionnalise par des amino-acides hydrophobes. |
| EP2313487B1 (en) | 2008-07-16 | 2018-04-04 | Children's Medical Center Corporation | Organ mimic device with microchannels and methods of use |
| WO2012166903A1 (en) * | 2011-06-02 | 2012-12-06 | President And Fellows Of Harvard College | Methods and uses for ex vivo tissue culture systems |
| PL221351B1 (pl) | 2012-03-14 | 2016-03-31 | Politechnika Warszawska | Sposób otrzymywania nanocząstek polisacharydowych |
| BR122021014396B1 (pt) * | 2012-10-11 | 2022-07-05 | Daiichi Sankyo Company, Limited | Compostos intermediários ligantes de fármacos, e ligante |
| US9872924B2 (en) | 2012-10-19 | 2018-01-23 | Daiichi Sankyo Company, Limited | Antibody-drug conjugate produced by binding through linker having hydrophilic structure |
| BR112016013482B1 (pt) | 2014-01-31 | 2022-04-19 | Daiichi Sankyo Company, Limited | Conjugado de anticorpo anti-her2-fármaco, fármacos antitumor e/ou anticâncer e composição farmacêutica |
| JP6948951B2 (ja) | 2015-05-04 | 2021-10-13 | ファイザー・インク | Ｂ群レンサ球菌多糖−タンパク質コンジュゲート、コンジュゲートを生成するための方法、コンジュゲートを含む免疫原性組成物、およびそれらの使用 |
| IL290959B2 (en) | 2015-06-29 | 2023-04-01 | Daiichi Sankyo Co Ltd | Preparations containing antibody-drug conjugates and methods for their production |
| US11273155B2 (en) | 2016-12-12 | 2022-03-15 | Daiichi Sankyo Company, Limited | Combination of antibody-drug conjugate and immune checkpoint inhibitor |
| BR112019012847A2 (pt) | 2017-01-17 | 2019-12-10 | Daiichi Sankyo Co Ltd | anticorpo ou fragmento funcional do anticorpo, polinucleotídeo, vetor de expressão, células hospedeiras, método para produção de um anticorpo de interesse ou de um fragmento funcional do anticorpo e para produção de um conjugado de anticorpo-fármaco, conjugado de anticorpo-fármaco, composição farmacêutica, fármaco antitumoral, e, método de tratamento de um tumor. |
| TWI794230B (zh) | 2017-05-15 | 2023-03-01 | 日商第一三共股份有限公司 | 抗ｃｄｈ６抗體及抗ｃｄｈ６抗體-藥物結合物、以及其製造方法 |
| SG11202000997YA (en) | 2017-08-31 | 2020-03-30 | Daiichi Sankyo Co Ltd | Improved method for producing antibody-drug conjugate |
| US11318212B2 (en) | 2017-08-31 | 2022-05-03 | Daiichi Sankyo Company, Limited | Method for producing antibody-drug conjugate |
| CN112351999A (zh) | 2018-05-18 | 2021-02-09 | 第一三共株式会社 | 抗-muc1抗体-药物缀合物 |
| TWI822822B (zh) | 2018-07-31 | 2023-11-21 | 日商第一三共股份有限公司 | 抗體-藥物結合物之用途 |
| CN109481691A (zh) * | 2018-11-20 | 2019-03-19 | 珠海天香苑生物科技发展股份有限公司 | 吉西他滨-羧甲基多糖共轭物、制备方法及其用途 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE195324T1 (de) * | 1993-02-26 | 2000-08-15 | Drug Delivery System Inst Ltd | Polysaccharidderivat und wirkstoffträger |
| SG50747A1 (en) * | 1995-08-02 | 1998-07-20 | Tanabe Seiyaku Co | Comptothecin derivatives |
| CA2192725C (en) * | 1995-12-28 | 2004-04-20 | Kenji Tsujihara | Camptothecin derivatives |
| JP4420472B2 (ja) * | 1996-04-15 | 2010-02-24 | 旭化成株式会社 | 薬物複合体 |
| TW527183B (en) * | 1996-06-06 | 2003-04-11 | Daiichi Seiyaku Co | Drug complex |
| CN1058038C (zh) * | 1996-12-31 | 2000-11-01 | 中国科学院感光化学研究所 | 低收缩性光固化涂层材料及其制法和用途 |
| CA2333321A1 (en) * | 1998-05-22 | 1999-12-02 | Daiichi Pharmaceutical Co., Ltd. | Drug complex |
-
2002
- 2002-08-14 TW TW091118260A patent/TWI313609B/zh not_active IP Right Cessation
- 2002-08-15 AR ARP020103077A patent/AR035137A1/es unknown
- 2002-08-16 BR BR0212036-4A patent/BR0212036A/pt not_active IP Right Cessation
- 2002-08-16 UA UA2004032071A patent/UA75450C2/uk unknown
- 2002-08-16 RU RU2004108141/15A patent/RU2275913C2/ru not_active IP Right Cessation
- 2002-08-16 NZ NZ530947A patent/NZ530947A/en not_active IP Right Cessation
- 2002-08-16 WO PCT/JP2002/008309 patent/WO2003015826A1/en active IP Right Grant
- 2002-08-16 CN CNB028163176A patent/CN100372570C/zh not_active Expired - Fee Related
- 2002-08-16 AU AU2002328093A patent/AU2002328093B2/en not_active Ceased
- 2002-08-16 KR KR10-2004-7002566A patent/KR20040027972A/ko not_active Application Discontinuation
- 2002-08-16 MX MXPA04001599A patent/MXPA04001599A/es unknown
- 2002-08-16 IL IL16014802A patent/IL160148A0/xx unknown
- 2002-08-16 CA CA002457056A patent/CA2457056C/en not_active Expired - Fee Related
- 2002-08-16 EP EP02762786A patent/EP1418947A1/en not_active Withdrawn
- 2002-08-16 PL PL02368319A patent/PL368319A1/xx not_active Application Discontinuation
- 2002-08-16 HU HU0401351A patent/HUP0401351A3/hu unknown
-
2004
- 2004-02-04 ZA ZA200400917A patent/ZA200400917B/en unknown
- 2004-03-19 NO NO20041194A patent/NO20041194L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| RU2004108141A (ru) | 2005-04-20 |
| PL368319A1 (en) | 2005-03-21 |
| NZ530947A (en) | 2006-04-28 |
| HUP0401351A2 (hu) | 2004-12-28 |
| CA2457056A1 (en) | 2003-02-27 |
| NO20041194L (no) | 2004-03-19 |
| AU2002328093B2 (en) | 2005-05-05 |
| HUP0401351A3 (en) | 2011-02-28 |
| KR20040027972A (ko) | 2004-04-01 |
| UA75450C2 (en) | 2006-04-17 |
| CA2457056C (en) | 2008-07-22 |
| BR0212036A (pt) | 2004-08-17 |
| CN100372570C (zh) | 2008-03-05 |
| WO2003015826A1 (en) | 2003-02-27 |
| TWI313609B (en) | 2009-08-21 |
| CN1545423A (zh) | 2004-11-10 |
| EP1418947A1 (en) | 2004-05-19 |
| RU2275913C2 (ru) | 2006-05-10 |
| ZA200400917B (en) | 2004-08-25 |
| MXPA04001599A (es) | 2004-07-08 |
| IL160148A0 (en) | 2004-07-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR035137A1 (es) | Composicion farmaceutica para inhibir metastasis o prevenir recurrencia de tumor maligno | |
| CY1116103T1 (el) | Υποκατεστημενα παραγωγα 1,2,3,4-τετραϋδροϊσοκινολινης | |
| ECSP10010254A (es) | Compuestos que contienen quinoxalina como inhibidores del virus de la hepatitis c | |
| CY1109457T1 (el) | Παραγωγο aminoαλκοολης ή παραγωγο φωσφονικου οξεος και φαρμακευτικη συνθεση που τα περιεχει | |
| BR0315547A (pt) | Derivados de quinolina como antagonistas de crth2 | |
| AR061238A1 (es) | Compuestos de oxilmilo macrociclico inhibidores de proteasa de hepatitis c | |
| AR035885A1 (es) | Derivados de 4-amino-5-fenil-7-ciclobutilpirrolo (2,3-d)pirimidina, un proceso para su preparacion, una composicion farmaceutica y el uso de dichos derivados para la preparacion de una composicion farmaceutica | |
| TW200700393A (en) | Novel cis-2,4,5-triaryl-imidazolines | |
| ECSP066424A (es) | Derivados de 2,4-di-(hetero)-aril-amino-pirimidina como inhibidores de zap-70 y/o syk | |
| EP1481965A4 (en) | AROMATIC AMINO ACID DERIVATIVES AND MEDICAL COMPOSITIONS | |
| TR200103186T2 (tr) | MEK enzimlerinin inhibitörleri olarak kinolin türevleri | |
| TR200103390T2 (tr) | Proteaz inhibitörleri olan yeni bileşikler ve terkipler. | |
| EA201170607A1 (ru) | Акриламидопроизводные, применимые как ингибиторы перехода митохондриальной проницаемости | |
| TR199902606T2 (xx) | Farnesil transferaz� engelleyici kinazolinonlar. | |
| HUP0105231A2 (hu) | Heteroaril-szubsztituált kinolin-2-on-származék rákellenes szerek és a vegyületeket tartalmazó gyógyszerkészítmények | |
| BRPI0313942C1 (pt) | derivados de benzimidazol úteis como agentes antiproliferativos, seus processos de preparação, composição farmacêutica compreendendo os mesmos e usos dos referidos compostos nas preparações de composições farmacêuticas | |
| CO5631443A2 (es) | Derivados de 7-aril-3,9-diazabiciclo (3.3.1) non-6-eno y su uso como inhibidores de renina en el tratamiento de enfermedades de hipertension, cardiovasculares o renales | |
| UY30391A1 (es) | Compuesto de oximilo aciclico inhibidores de proteasa de hepatitis c | |
| CO6270285A2 (es) | Derivados de 4-[(4-amino-1, 3, 5-triazin-2-il)amino]-n-arilmetilcicloalquilcarboxamida | |
| WO2018005279A1 (en) | Combination chemotherapies | |
| MX2010008108A (es) | Inhibidores de proteasa de serina de tripéptido de virus de hepatitis c (hcv) que contienen heteroarilo. | |
| GEP20125548B (en) | New dihidroindolone compounds, a process for its preparation and pharmaceutical compositions containing them | |
| ATE404536T1 (de) | Substituierte chinolinderivate als inhibitoren von mitotischem kinesin | |
| BR0314352A (pt) | Indóis 2,7-substituìdos e seu uso como moduladores de 5-ht6 | |
| EA200702672A1 (ru) | Производные индола, обладающие противоопухолевой активностью |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |